These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 12680149)
1. Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer. Furuya Y; Kawauchi Y; Fuse H Anticancer Res; 2003; 23(1B):577-81. PubMed ID: 12680149 [TBL] [Abstract][Full Text] [Related]
2. Changes in cell proliferation and apoptosis during local progression of prostate cancer. Kaibuchi T; Furuya Y; Akakura K; Masai M; Ito H Anticancer Res; 2000; 20(2B):1135-9. PubMed ID: 10810410 [TBL] [Abstract][Full Text] [Related]
3. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer. Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375 [TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
5. [Treatment results of combined hormone and chemotherapy in patients with advanced prostate cancer]. Uekado Y Hinyokika Kiyo; 1991 Aug; 37(8):825-31. PubMed ID: 1957724 [TBL] [Abstract][Full Text] [Related]
6. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H; Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423 [TBL] [Abstract][Full Text] [Related]
7. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354 [TBL] [Abstract][Full Text] [Related]
8. [Combination therapy with hormonal, radiation and chemotherapy for stage C prostate cancer]. Iwasawa T; Matsumoto H Hinyokika Kiyo; 1996 Nov; 42(11):869-74. PubMed ID: 8973937 [TBL] [Abstract][Full Text] [Related]
9. [Combined hormone and chemotherapy for the patients with advanced prostate cancer]. Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755 [TBL] [Abstract][Full Text] [Related]
10. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer. Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806 [TBL] [Abstract][Full Text] [Related]
11. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer]. Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583 [TBL] [Abstract][Full Text] [Related]
12. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. Boel K; Van Poppel H; Goethuys H; Derluyn J; Vandenbroucke F; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L Anticancer Res; 1999; 19(3B):2157-61. PubMed ID: 10472324 [TBL] [Abstract][Full Text] [Related]
13. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. Koivisto P; Visakorpi T; Rantala I; Isola J J Pathol; 1997 Sep; 183(1):51-6. PubMed ID: 9370947 [TBL] [Abstract][Full Text] [Related]
14. [Retrospective clinical evaluation of prognosis factors in stage D2 prostatic cancer treated with endocrine therapy]. Kudo K; Nagata M; Hayashi N; Imamura H; Kimura M; Mimura H; Matsuyama K; Shishido S; Chino I Hinyokika Kiyo; 1991 Feb; 37(2):129-34. PubMed ID: 1710871 [TBL] [Abstract][Full Text] [Related]
15. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987 [TBL] [Abstract][Full Text] [Related]
17. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED; J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721 [TBL] [Abstract][Full Text] [Related]